Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Feb 27, 2023; 15(2): 142-162
Published online Feb 27, 2023. doi: 10.4240/wjgs.v15.i2.142
Published online Feb 27, 2023. doi: 10.4240/wjgs.v15.i2.142
Comprehensive multimodal management of borderline resectable pancreatic cancer: Current status and progress
Hong-Yu Wu, Jin-Zheng Li, Qi-Long Zhai, Jing-Yuan Ye, Si-Yuan Zheng, Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
Jin-Wei Li, Department of Neurosurgery, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou 545000, Guangxi Province, China
Kun Fang, Department of Surgery, Yinchuan Maternal and Child Health Hospital, Yinchuan 750000, Ningxia, China
Author contributions: Wu HY, Zhai QL and Li JW were responsible for collating literatures, producing figures and tables and writing the paper; Ye JY and Zheng SY performed the literature search and language translation; Li JZ and Fang K reviewed the paper and approved the vision of the article to be published.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kun Fang, MD, Research Assistant, Surgical Oncologist, Department of Surgery, Yinchuan Maternal and Child Health Hospital, No. 56 Wenhua West Road, Xingqing District, Yinchuan 750000, Ningxia, China. k99ftl@163.com
Received: October 13, 2022
Peer-review started: October 13, 2022
First decision: November 15, 2022
Revised: November 23, 2022
Accepted: January 11, 2023
Article in press: January 11, 2023
Published online: February 27, 2023
Processing time: 136 Days and 20.1 Hours
Peer-review started: October 13, 2022
First decision: November 15, 2022
Revised: November 23, 2022
Accepted: January 11, 2023
Article in press: January 11, 2023
Published online: February 27, 2023
Processing time: 136 Days and 20.1 Hours
Core Tip
Core Tip: Borderline resectable pancreatic cancer (BRPC) is a type of pancreatic cancer with specific biological characteristics. To date, there is no unified comprehensive management for this disease. Thus, an evaluation of BRPC resection and neoadjuvant therapy (NAT) is needed. This review summarizes new resection methods and different NAT schemes, including treatment efficacy evaluation and management. This study also discusses the current progress of surgical treatment and the use of multidisciplinary teams to provide comprehensive multimodal management of BRPC treatment.